NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's SGX302 Phase 2a Psoriasis Study Results
TL;DR
Soligenix's SGX302 offers a noncarcinogenic photodynamic therapy advantage for psoriasis, potentially capturing market share with its well-tolerated, first-in-class treatment.
SGX302 uses visible light-activated synthetic hypericin in an optimized gel formulation, applied twice weekly over 18 weeks with no drug-related adverse events reported.
This therapy provides a safer, noncarcinogenic treatment option for psoriasis patients, improving quality of life through an enhanced patient experience and clinical efficacy.
SGX302 introduces a novel photodynamic therapy using synthetic hypericin activated by visible light, representing an innovative approach to treating skin conditions.
Found this article helpful?
Share it with your network and spread the knowledge!
SGX302 is an investigational therapy using synthetic hypericin as a first-in-class photodynamic therapy mechanism to treat mild-to-moderate psoriasis.
In cohort 3, SGX302 was well tolerated by all patients with no drug-related adverse events identified during treatment, and clinical improvements were observed with an optimized gel formulation.
SGX302 utilizes visible light-activated synthetic hypericin, making it a photodynamic therapy that is described as noncarcinogenic.
An optimized gel formulation was designed to improve patient experience with both easier dispensation and skin application.
Cohort 3 enrolled four additional patients who applied SGX302 gel to psoriasis lesions twice a week over an 18-week period, the same duration as prior cohorts.
SGX302 is being developed by Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
The results underscore the potential of SGX302 as a noncarcinogenic, photodynamic treatment for psoriasis, demonstrating safety and clinical improvements with an optimized formulation.
Curated from InvestorBrandNetwork (IBN)
